These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 31642065

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tocilizumab in the management of posttransfusion hyperhemolysis syndrome in sickle cell disease: The experience so far.
    Meenan J, Hall R, Badle S, Chatterjee B, Win N, Tsitsikas DA.
    Transfusion; 2022 Mar; 62(3):546-550. PubMed ID: 35092617
    [Abstract] [Full Text] [Related]

  • 3. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.
    Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP.
    Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature.
    Unnikrishnan A, Pelletier JPR, Bari S, Zumberg M, Shahmohamadi A, Spiess BD, Michael MJ, Harris N, Harrell D, Mandernach MW.
    Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787
    [Abstract] [Full Text] [Related]

  • 6. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.
    Gupta S, Fenves A, Nance ST, Sykes DB, Dzik WS.
    Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab.
    Sivapalaratnam S, Linpower L, Sirigireddy B, Agapidou A, Jain S, Win N, Tsitsikas DA.
    Br J Haematol; 2019 Sep; 186(6):e212-e214. PubMed ID: 31368112
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
    Vlachaki E, Gavriilaki E, Kafantari K, Adamidou D, Tsitsikas D, Chasapopoulou E, Anagnostopoulos A, Tsapas A.
    Hemoglobin; 2018 Sep; 42(5-6):339-341. PubMed ID: 30626228
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Utility of hemoglobin electrophoresis to distinguish between severe delayed hemolytic transfusion reaction versus hyperhemolysis syndrome.
    Lukin R, Law JY, Lokhandwala PM.
    Transfus Apher Sci; 2024 Jun; 63(3):103919. PubMed ID: 38582651
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review.
    Win N, New H, Lee E, de la Fuente J.
    Transfusion; 2008 Jun; 48(6):1231-8. PubMed ID: 18373500
    [Abstract] [Full Text] [Related]

  • 15. Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion.
    Chonat S, Arthur CM, Zerra PE, Maier CL, Jajosky RP, Yee MEM, Miller MJ, Josephson CD, Roback JD, Fasano R, Stowell SR.
    Transfus Clin Biol; 2019 May; 26(2):130-134. PubMed ID: 30979566
    [Abstract] [Full Text] [Related]

  • 16. Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: A single-center case series.
    Lapite A, Bhar S, Fasipe T.
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31061. PubMed ID: 38840429
    [Abstract] [Full Text] [Related]

  • 17. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease.
    Noizat-Pirenne F, Bachir D, Chadebech P, Michel M, Plonquet A, Lecron JC, Galactéros F, Bierling P.
    Haematologica; 2007 Dec; 92(12):e132-5. PubMed ID: 18055978
    [Abstract] [Full Text] [Related]

  • 18. Hyperhemolysis syndrome in patients with sickle cell anemia: report of three cases.
    Santos B, Portugal R, Nogueira C, Loureiro M.
    Transfusion; 2015 Jun; 55(6 Pt 2):1394-8. PubMed ID: 25677578
    [Abstract] [Full Text] [Related]

  • 19. "Don't Add Fuel to the Fire"- Hyperhemolysis Syndrome in a Pregnant Woman with Compound Sickle Cell Disease/β0-Thalassemia: Case Report and Review of the Literature.
    Rihsling A, Simeunovic H, Sanchez S, Henny C, Lejon Crottet S, Mansouri Teleghani B, Daskalakis M, Müller M, Raio L, Rovó A.
    Acta Haematol; 2024 Jun; 147(3):378-387. PubMed ID: 37839398
    [Abstract] [Full Text] [Related]

  • 20. A case of hyperhemolysis syndrome in sickle cell disease and concomitant COVID-19.
    Green A, Jones H, Nero A, Ibrahim IF, Sarode R, Scheid LM, Webb CB, Adkins BD, Yates SG.
    Transfus Apher Sci; 2023 Aug; 62(4):103712. PubMed ID: 37149492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.